Zoll CEO Packer on device tax repeal efforts: No pessimists on the front lines

December 20, 2012 by Arezu Sarvestani

Zoll CEO Rick Packer says that tax repeal advocates on the front lines of the discussions with Washington are optimistic that the levy on device makers will be addressed before it hits in January.

Zoll CEO Richard Packer

As the medical device excise tax creeps closer to its planned launch date, all eyes are on Congress to see whether medtech lobbying efforts will yield a win for the industry.

While lawmakers weigh the tax and argue their way toward the so-called fiscal cliff, device industry stakeholders are placing their bets on whether or not the excise tax will survive until January.

Sign up to get our free newsletters delivered right to your inbox.

A MassDevice.com snap poll also showed substantial pessimism that the tax would be repealed or that the industry's influence in Washington, D.C., would get very far.

"I would ask whether those people are close to the fight or not," medical device maker Zoll Medical's CEO Richard Packer told MassDevice.com in an interview. "Most people don't know what's going on, they don't recognize the magnitude of the letter that the Democratic senators sent to leadership, they don't understand those things.  So they see tax accountants getting ready to figure this out they just assume that the tax is fait accompli."

Packer remains steadfast in optimism that the tax is not 'fait accompli,' or a done deal. He remains in conversations with lawmakers and their staff, and from his perspective the outlook is pretty rosy, he told us.

Comments

Features

David Green tells MassDevice.com about the decision to split Harvard Bioscience and Harvard Apparatus Regenerative Technology, his choice to move over to the new entity and why regenerative technologies are poised to transform medicine.

Medtech veteran Dave Johnson has been with Alliqua Biomedical for less than 2 years, during which time he's overseen a major hiring spree, 3 business development deals and the company's 1st acquisition. In an interview with MassDevice.com, Johnson talks about his step-by-step perspective and where he hopes Alliqua will be in 5 years.

MassDevice.com brought together 4 of the most influential leaders in medtech to discuss the future of the industry on July 15, 2014 at DeviceTalks Boston.

Boston Millennia's managing general partner Dana Callow discusses the 11-year journey to bring CardioMEMs implantable heart monitor to market and what his venture capital firm sees for the future of medtech investment.

Haemonetics CEO Brian Concannon discusses how the company will transform blood management in the coming years at MassDevice.com's DeviceTalks Boston event.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp